Literature DB >> 7882335

Replacement of the p16/CDKN2 gene suppresses human glioma cell growth.

W Arap1, R Nishikawa, F B Furnari, W K Cavenee, H J Huang.   

Abstract

The p16/CDKN2 gene has many features of a growth suppressor gene: it maps to 9p21, a frequent region of loss of heterozygozity in a variety of tumor types; it encodes an inhibitor of cyclin-dependent kinase 4; and its homozygous deletion is common in tumor-derived cell lines. However, the lower frequency of alteration of the gene in primary tumor tissue as compared to the cognate tumor cell lines has brought this interpretation into question. We have assessed the growth suppressive function of p16/CDKN2 by gene transfer. The introduction of full-length p16/CDKN2 cDNA caused marked growth suppression in p16/CDKN2-null human glioma cells, but was without significant effect in those cells with endogenous wild-type p16/CDKN2 alleles. These results provide functional evidence in support of the hypothesis that the p16/CDKN2 gene is a functional growth suppressor gene, at least in gliomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7882335

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Lack of the DNA repair protein O6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors.

Authors:  J R Silber; A Blank; M S Bobola; B A Mueller; D D Kolstoe; G A Ojemann; M S Berger
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Sense p16 and antisense uPAR bicistronic construct inhibits angiogenesis and induces glioma cell death.

Authors:  Narasimharao Nalabothula; Sajani S Lakka; Dzung H Dinh; Meena Gujrati; William C Olivero; Jasti S Rao
Journal:  Int J Oncol       Date:  2007-03       Impact factor: 5.650

3.  P16 deletion and mutation analysis in human brain tumors.

Authors:  F G Barker; P Chen; F Furman; K D Aldape; M S Edwards; M A Israel
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

4.  Expression of p16 gene and Rb protein in gastric carcinoma and their clinicopathological significance.

Authors:  Xiu-Sheng He; Ying-Hui Rong; Qi Su; Qiao Luo; Dong-Mei He; Yan-Lan Li; Yan Chen
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

5.  Conditional expression of the tumor suppressor p16 in a heterotopic glioblastoma model results in loss of pRB expression.

Authors:  Matthias Simon; Christian Simon; Gertraud Köster; Volkmar H J Hans; Johannes Schramm
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

Review 6.  Delivery of cell cycle genes to block astrocytoma growth.

Authors:  J Fueyo; C Gomez-Manzano; T J Liu; W K Yung
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

7.  CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.

Authors:  H Miettinen; J Kononen; P Sallinen; H Alho; P Helen; H Helin; H Kalimo; L Paljärvi; J Isola; H Haapasalo
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

8.  Exogenous expression of p16INK4a is associated with decrease in telomerase activity.

Authors:  H Sawa; H Kamada; T A Ohshima; A Noguchi; N Itoh; K Saruta; M Hara; I Saito
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

Review 9.  Antisense oncogene and tumor suppressor gene therapy of cancer.

Authors:  W W Zhang
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

10.  Comparison of the inhibitory effects of three transcriptional variants of CDKN2A in human lung cancer cell line A549.

Authors:  Wei Zhang; Jing Zhu; Jing Bai; Hui Jiang; Fangli Liu; An Liu; Peng Liu; Guohua Ji; Rongwei Guan; Donglin Sun; Wei Ji; Yang Yu; Yan Jin; Xiangning Meng; Songbin Fu
Journal:  J Exp Clin Cancer Res       Date:  2010-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.